Last updated: about 1 month ago
AstraZeneca's 6-K Report: Imfinzi Shines in Phase III MATTERHORN Trial for Gastric Cancer
Explore AstraZeneca's 6-K filing detailing Imfinzi's Phase III MATTERHORN trial results, showing significant improvements in event-free survival for gastric cancer patients.